Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen.
Liu KJ, Li HR, Tan QQ, Jiang T, Peng KC, Chen HJ, Zhou Q, Zhang XC, Zheng Z, Chen SY, Zheng X, Zheng HB, Mao BB, Gong LL, Chen XW, Wu W, Wu YL, Jia J, Yang JJ.
Liu KJ, et al. Among authors: tan qq.
Lung Cancer. 2024 Sep;195:107933. doi: 10.1016/j.lungcan.2024.107933. Epub 2024 Aug 22.
Lung Cancer. 2024.
PMID: 39191079
Free article.